...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors
【24h】

The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors

机译:糖皮质激素受体的表达受前列腺肿瘤中活性雄激素受体信号的负调控

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The glucocorticoid and androgen receptors (GR and AR) can commonly regulate up to 50% of their target genes in prostate cancer (PCa) cells. GR expression is stimulated by castration therapy, which has been proposed to be one mechanism that compensates for AR signaling blockade and promotes castration-resistant PCa (CRPC) progression. However, whether GR functions as a driver for CRPC or a marker reflecting AR activity remains unclear. Here, we applied PCa tissue microarrays to show that GR protein levels were elevated by castration therapy, but reduced to pre-castration levels when tumors were at the CRPC stage. Using subrenal capsule xenograft models, we showed that GR expression was inversely correlated with AR and PSA expressions. GR expression levels are not associated with tumor invasion and metastasis phenotypes. In castration-resistant C4-2 xenografts expressing AR shRNA, regressing tumors induced by AR knockdown expressed higher levels of GR and lower levels of PSA than non-regressing tumors. Immunoblotting and real-time PCR assays further showed that AR knockdown or AR antagonists increased GR expression at both mRNA and protein levels. ChIP combined with DNA sequencing techniques identified a negative androgen responsive element (nARE) 160K base pairs upstream of the GR gene. Gel shift assays confirmed that AR directly interacted with the nARE and luciferase assays demonstrated that the nARE could mediate transcription repression by ligand-activated AR. In conclusion, GR expression is negatively regulated by AR signaling and may serve as a marker for AR signaling in prostate tumors.
机译:糖皮质激素和雄激素受体(GR和AR)通常可以调节前列腺癌(PCa)细胞中多达50%的靶基因。 GR表达受到去势疗法的刺激,已被认为是补偿AR信号传导阻滞并促进去势抵抗性PCa(CRPC)进展的一种机制。但是,是否GR是作为CRPC的驱动程序还是反映AR活动的标记尚不清楚。在这里,我们应用PCa组织微阵列显示去势疗法可提高GR蛋白水平,但当肿瘤处于CRPC阶段时可降低至cast割前水平。使用肾下囊异种移植模型,我们显示GR表达与AR和PSA表达成反比。 GR表达水平与肿瘤浸润和转移表型无关。在表达AR shRNA的去势抵抗性C4-2异种移植物中,AR敲低诱导的退化性肿瘤比非退化性肿瘤表达更高的GR水平和更低的PSA水平。免疫印迹和实时PCR分析进一步显示,AR敲低或AR拮抗剂在mRNA和蛋白水平上均可增加GR表达。 ChIP与DNA测序技术相结合,鉴定出GR基因上游的负雄激素反应元件(nARE)160K碱基对。凝胶位移分析证实AR与nARE直接相互作用,荧光素酶分析表明nARE可以通过配体激活的AR介导转录抑制。总之,GR表达受AR信号负调控,并可作为前列腺肿瘤中AR信号的标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号